Christopher Kim, MD
Cardiovascular Disease · Farmington, UTNPI 1457650442
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 69.5% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $7,887 and has fallen 87.4% since, to $997 in 2025. Among cardiovascular disease clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 295 payments — averaging $121.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$25K
- Endologix LLC$6K
- Abbott$2K
- Cook Medical LLC$623
- Boston Scientific$423
- Inari Medical, Inc.$250
- plus $1K from 18 others
Across 40 payments — averaging $2194.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$39K
- Novartis$25K
- Boston Scientific$16K
- GSK$8K
What the payments were for
- Consulting fees$5,07514%
- Speaking & faculty fees$20,92558%
- Travel & lodging$1,8455%
- Food & beverage$8,06022%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 131 | $24,944 |
| Endologix LLC | 16 | $6,315 |
| Abbott | 69 | $1,945 |
| Cook Medical LLC | 3 | $623 |
| Boston Scientific | 25 | $423 |
| Inari Medical, Inc. | 5 | $250 |
| Cardiovascular Systems Inc. | 9 | $232 |
| Cvrx, Inc. | 3 | $205 |
| Angiodynamics, Inc. | 2 | $172 |
| Reflow Medical Inc | 1 | $116 |
| Terumo Medical Corporation | 5 | $109 |
| Penumbra, Inc. | 1 | $104 |
| Bard Peripheral Vascular, Inc. | 6 | $97 |
| Novartis | 4 | $78 |
| Cordis US CORP. | 3 | $52 |
| Philips North America LLC | 1 | $44 |
| Cardinal Health 200 LLC | 3 | $36 |
| Surmodics, Inc. | 1 | $33 |
| Livanova USA, Inc. | 2 | $30 |
| Esaote North America, Inc. | 1 | $23 |
| Abiomed | 1 | $22 |
| BD | 1 | $21 |
| Bayer | 1 | $16 |
| Turn-key Medical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$21,119
- AFX2 Bifurcated Endograft System$2,975
- Ovation$2,410
- RESOLUTE ONYX$1,391
- Hemospray$594
- AFX$397
- FlowTriever$134
- ClotTriever$134
- Auryon Laser System 100-120 Vac$132
- Abre$130
- Barostim Neo System$129
- Alto Abdominal Stent Graft System$125
- Supera peripheral stent system$115
- Penumbra System$104
- Indigo$104
How this compares
$35,905 in reported general payments places this provider in the 90th percentile of 131 cardiovascular disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 52 | $58,375 |
| XareltoRivaroxaban | 45 | $55,832 |
| ClopidogrelClopidogrel Bisulfate | 187 | $1,650 |
| Atorvastatin Calcium | 102 | $949 |
| Carvedilol | 128 | $833 |
| Metoprolol Succinate | 79 | $707 |
| Amiodarone Hcl | 52 | $598 |
| Rosuvastatin Calcium | 46 | $548 |
| Ezetimibe | 23 | $525 |
| Potassium Chloride | 21 | $476 |
| SotalolSotalol Hcl | 12 | $339 |
| Lisinopril | 51 | $299 |
| Irbesartan | 15 | $252 |
| Furosemide | 47 | $244 |
| Losartan Potassium | 23 | $234 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Farmington
- Daniel FronkFarmington$13K
- John RyanSalt Lake City$1.4M
- Robert FowlesSalt Lake City$611K
- Brian WhisenantMurray$416K
- Andrew BehuninDraper$192K
- Jeffrey OsbornSalt Lake City$69K
- James FangSalt Lake City$67K
- Joseph MuhlesteinMurray$65K
- Hannah RaaschSalt Lake City$62K
- Divya Ratan VermaMurray$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.